组蛋白甲基转移酶SMYD3在子宫内膜癌中的表达及意义

叶伟标; 李广柳; 朱莹; 禤文婷; 李仲均

doi:10.19538/j.fk2025100115

PDF(3573 KB)

中国实用妇科与产科杂志 ›› 2025, Vol. 41 ›› Issue (10) : 1031-1033. DOI: 10.19538/j.fk2025100115

论著

组蛋白甲基转移酶SMYD3在子宫内膜癌中的表达及意义

叶伟标 ¹ ,
李广柳 ¹ ,
朱莹 ¹ ,
禤文婷 ¹ ,
李仲均 ¹^,²

作者信息 +

Expression of histone methyltransferase SMYD3 in endometrial carcinoma and its significance

Author information +

文章历史 +

摘要

目的探讨组蛋白甲基转移酶SMYD3在子宫内膜癌组织中的表达及意义。方法选取2014年1月至2020年12月于南方医科大学第十附属医院行手术诊疗的子宫内膜癌患者85例，采用免疫组织化学染色技术分别检测子宫内膜癌组织、不典型增生子宫内膜组织、正常子宫内膜组织中SMYD3的表达情况，分析其与患者临床病理特征和预后的关系。结果 SMYD3在子宫内膜癌组织中阳性表达率为83.53%（71/85），高于不典型增生子宫内膜组织阳性表达率43.33%（13/30）和正常子宫内膜组织阳性表达率26.67%（8/30），差异具有统计学意义（P<0.05）。在子宫内膜癌患者中，SMYD3表达水平与国际妇产科联盟（FIGO）分期、淋巴脉管间隙浸润、淋巴结转移相关（P<0.05）。SMYD3高表达的患者总生存时间低于SMYD3低表达患者（P<0.05）。结论 SMYD3在子宫内膜癌中呈高表达状态，且与肿瘤进展和预后不良密切相关，提示其可能作为子宫内膜癌潜在预后指标和治疗靶点。

Abstract

Objective To investigate the expression and significance of histone methyltransferase SMYD3 in endometrial carcinoma. Methods Totally 85 patients with endometrial cancer who underwent surgical treatment at The Tenth Affiliated Hospital，Southern Medical University from January 2014 to December 2020 were selected.The expression of SMYD3 in endometrial carcinoma tissue，atypical endometrial hyperplasia tissue，and normal endometrium tissue was assessed by immunohistochemical staining. The correlation between SMYD3 expression and clinicopathological characteristics and prognosis of patients was analyzed. Results The positive rate of SMYD3 expression in the endometrial carcinoma tissue was 83.53%，which was higher than that in atypical endometrial hyperplasia tissue（43.33%） and normal endometrium tissue （26.67%），and the difference was statistically significant （P<0.05）. The expression level of SMYD3 was associated with FIGO stage，lymphovascular space involvement，and lymph node metastasis in patients with endometrial carcinoma （P<0.05）. The patients with higher SMYD3 expression had shorter overall survival time than those with lower SMYD3 expression（P<0.05）. Conclusion The expression of SMYD3 is high in endometrial carcinoma，which is closely correlated with tumour progression and poor prognosis，suggesting that it can be used as a potential prognostic indicator and therapeutic target.

导出引用

叶伟标, 李广柳, 朱莹, 等. 组蛋白甲基转移酶SMYD3在子宫内膜癌中的表达及意义[J]. 中国实用妇科与产科杂志. 2025, 41(10): 1031-1033 https://doi.org/10.19538/j.fk2025100115

YE Wei-biao, LI Guang-liu, ZHU Ying, et al. Expression of histone methyltransferase SMYD3 in endometrial carcinoma and its significance[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2025, 41(10): 1031-1033 https://doi.org/10.19538/j.fk2025100115

中图分类号： R737.3

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析

[1]	胡兆星, 张运征, 董莹莹, 等. 人工智能辅助下的子宫内膜癌诊疗新理念与新视角[J]. 中国实用妇科与产科杂志, 2025, 41(8):859-864. DOI:10.19538/j.fk2025080119. 本文引用 [2]

[2]	中国抗癌协会子宫体肿瘤专业委员会, 中国妇产科精准医学协会,长三角地区妇科质控委员会.子宫内膜癌手术治疗质量控制与评价标准中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6): 626-637. DOI: 10.19538/j.fk2024060113. 本文引用 [1]

[3]	Li B, Pan R, Zhou C, et al. SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer[J]. Future Oncol, 2018, 14(18): 1825-1834. DOI: 10.2217/fon-2017-0682. 本文引用 [1]

[4]	Yoshioka Y, Suzuki T, Matsuo Y, et al. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization[J]. Cancer Med, 2017, 6(7): 1665-1672. DOI: 10.1002/cam4.1099. 本文引用 [1]

[5]	Tsai CH, Chen YJ, Yu CJ, et al. SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation[J]. Cancer Res, 2016, 76(20):6043-6053. DOI: 10.1158/0008-5472.CAN-16-0500. 本文引用 [1]

[6]	Lyu T, Jiang Y, Jia N, et al. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters[J]. Int J Cancer, 2020, 146(6):1553-1567. DOI: 10.1002/ijc.32673. 本文引用 [1]

[7]	Beck T, Weikel W, Brumm C, et al. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA,PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC)[J]. Gynecol Oncol, 1994, 53(2):220-227. DOI:10.1006/gyno.1994.1119. 本文引用 [1]

[8]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231. DOI:10.3760/cma.j.cn112152-20240119-00035. 本文引用 [1]

[9]	杨婧, 李蓉. 子宫内膜增生症和早期子宫内膜癌患者的控制性超促排卵策略研究进展[J]. 中国实用妇科与产科杂志, 2024, 40(5):566-569. DOI:10.19538/j.fk2024050118. 本文引用 [1]

[10]	Hamamoto R, Saloura V, Nakamura Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis[J]. Nat Rev Cancer, 2015, 15(2):110-124. DOI:10.1038/nrc3884. 本文引用 [1]

[11]	Rubio-Tomás T. The SMYD family proteins in immunology:An update of their obvious and non-obvious relations with the immune system[J]. Heliyon, 2021, 7(6):e07387. DOI:10.1016/j.heliyon.2021.e07387. 本文引用 [1]

[12]	Fenizia C, Bottino C, Corbetta S, et al. SMYD3 promotes the epithelial-mesenchymal transition in breast cancer[J]. Nucleic Acids Res, 2019, 47(3):1278-1293. DOI:10.1093/nar/gky1221. 本文引用 [1]

[13]	Zhu Y, Zhu MX, Zhang XD, et al. SMYD 3 stimulates EZR and LOXL2 transcription to enhance proliferation,migration,and invasion in esophageal squamous cell carcinoma[J]. Hum Pathol, 2016, 52:153-163. DOI: 10.1016/j.humpath.2016.01.012. 本文引用 [1]

[14]	Sarris ME, Moulos P, Haroniti A, et al. Smyd3 Is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development[J]. Cancer Cell, 2016, 29(3):354-366. DOI:10.1016/j.ccell.2016.01.013. 本文引用 [1]

[15]	Jiang Y, Lyu T, Che X, et al. Overexpression of SMYD3 in ovarian cancer is associated with ovarian cancer proliferation and apoptosis via methylating H3K4 and H4K20[J]. J Cancer, 2019, 10(17):4072-4084. DOI:10.7150/jca.29861. 本文引用 [1]

[16]	Huang Y, Tang M, Hu Z, et al. SMYD3 promotes endometrial cancer through epigenetic regulation of LIG4/XRCC4/XLF complex in non-homologous end joining repair[J]. Oncogenesis, 2024, 13(1):3-15. DOI:10.1038/s41389-023-00503-0. 本文引用 [1]